Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page
- Check5 days agoChange DetectedLocation entry updated from Padua, Italy to Padova, Italy to reflect local naming.SummaryDifference0.0%

- Check12 days agoChange DetectedAdded Melanoma as a related topic and MedlinePlus Genetics as a related topic. These additions enhance discoverability and contextual navigation without altering the core study details.SummaryDifference0.1%

- Check19 days agoChange DetectedNapoli, Italy, 80131 was updated to Naples, Italy, 80131, and the page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.3 was added; references to Melanoma, MedlinePlus Genetics, and Revision: v3.4.2 were removed. These appear to be administrative updates that do not change the study details or user interactions on the page.SummaryDifference0.1%

- Check41 days agoChange DetectedAdded Melanoma as a topic and included MedlinePlus Genetics as related topics.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded the 2026 NEJM article 'Nivolumab for Resected Stage III or IV Melanoma at 9 Years' to Publications and removed the 2025 ahead-of-print citation.SummaryDifference0.0%

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.